Highlights Semorinemab demonstrated a favorable and tolerable safety profile. However, semorinemab failed to slow the clinical progression of Alzheimer’s disease (AD) compared to placebo during the 73-week study period. This Journal Watch discusses a study entitled “ Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease ,” published in JAMA Neurology, 2022 . 1 Need for the study Tau proteins have always been a therapeutic target in AD.
The pathological tau spreads from cell to cell via the extracellular matrix in a prion-like manner. 2 Preclinical studies suggest that passive anti-tau antibodies could intercept pathologic extracellular tau species, thereby interrupting the spread of pathological tau deposition, manifesting as neurofibrillary tangles. 3 Semorinemab as a choice of intervention Semorinemab is a humanized IgG4 monoclonal antibody. It…
